Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients
| Autor: | Patricia Abellán Alfocea, A. Medina, Eduardo Redondo Cerezo, Flor Nogueras López, Maria Angeles López Garrido, Eva Julissa Ortega Suazo, Antonio Becerra Massare, M. Dolores Espinosa Aguilar |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Graft Rejection Male medicine.medical_specialty Basiliximab medicine.medical_treatment Biopsy Calcineurin Inhibitors Urology Renal function Tacrolimus Postoperative Complications medicine Humans Everolimus Renal Insufficiency Chronic Retrospective Studies Immunosuppression Therapy Sirolimus Transplantation business.industry Graft Survival Retrospective cohort study Immunosuppression Middle Aged Mycophenolic Acid medicine.disease Liver Transplantation Calcineurin Surgery Drug Therapy Combination Female business Immunosuppressive Agents medicine.drug Kidney disease Glomerular Filtration Rate |
| Zdroj: | Transplantation proceedings. 52(2) |
| ISSN: | 1873-2623 |
| Popis: | Background Calcineurin inhibitors have been implicated in acute and chronic kidney disease after liver transplant (LT). Everolimus (EVR) is a mammalian target of rapamycin inhibitor efficacious in preventing acute cellular rejection while preserving renal function among LT recipients. We evaluated the benefits on renal function of EVR immunosuppression in LT recipients. Methods We performed a retrospective and observational study in 477 LT recipients in Virgen de las Nieves Hospital from 2002 to 2019 on the use of EVR with tacrolimus minimization or withdrawal in LT recipients with renal dysfunction. The study included 100 patients starting EVR (20.96%); in 66 (66%) the indication was renal dysfunction. The change in renal function was assessed by estimated glomerular filtration rate. Statistical analyses were performed using SPSS 17.0 software (IBM, Munich, Germany). Results Fifty 8 patients received mycophenolate mofetil (87.8%), and tacrolimus therapy was stopped in 27 patients (40.9%). Induction therapy with basiliximab was administered in 41 patients (62.12%). There was significant difference between estimated glomerular filtration rate at the time of starting EVR and the first month at last follow-up (49.42 mL/min/1.73 m2 vs 75.27 mL/min/1.73 m2; P Conclusion This study showed that EVR is associated with a beneficial effect on glomerular filtration rate in both the short and long term in LT recipients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect